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At the time of Cobalt, Brachytherapy was competing with surgery, 
considered as a mini invasive treatment with a high local control.  
At the time of conformal radiotherapy, BT was the optimal technique 
to deliver a high dose to the target while sparing the bone structures 
and salivary glands then reducing complications and xerostomia. But it 
was often considered as an operator dependent technique as surgery 
was. 
Today, at the time of high tech Radiotherapy, BT is still competing 
with non invasive treatment by irradiation, IMRT or Stereotactic RT. 
Nevertheless, BT maintains its specific advantages wich makes it the 
most conformal technique, delivering an accelerated and hyperfrac-
tionated technique of irradiation, then increasing the therapeutic 
ratio. The development of imaging for 3D dosimetry and Conformal 
BT, as well of the possibility to prescribe the dose rate and optimise 
the dose distribution improves the dose distribution and results of the 
technique. 
The intraoperative placement of the catheters in the target mimics 
fiducials and improves the delineation of the target combined to the 
imagines and clinical exam during the procedure. This contributes, as 
well as the implantation inside the tissues to reduce the target 
volume with no ITV and a PTV equal to the CTV. The irradiation 
directly in the target also reduces the dose transmited to the bone 
and the salivary glands as well as the nominal dose.  
Considering the treatment of oropharyngeal cancer, BT delivered as a 
boost after IMRT can be considered as the optimal combination of 
treatment, competitive with stereotactic techniques.  
Last but not least, on an economic point of view, BT is less expensive 
than new high tech external beam techniques.  
This justifies to intensify the teaching of this technique then offering 
to the patients a panel of skilled brachytherapists able to perform the 
procedure with quality assurance control.  
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About one third of oropharyngeal carcinomas are diagnosed in early-
stage disease, amendable to curative treatment with either radical 
surgery or primary radiotherapy (RT). However, two thirds of patients 
present with locally advanced disease (clinical stage III or IV) and have 
a less favorable prognosis. Over the last decades, the management of 
locally advanced HNC has evolved towards approaches that offer the 
possibility of organ preservation, such as chemoradiotherapy. 
Although the prognosis of patients treated with RT for locally 
advanced HNC is continually improving, loco regional failure remains a 
major concern, certainly for the HPV negative tumors. Locoregional 
recurrences are mainly located in the high-dose prescription regions, 
suggesting the need for even higher doses in those areas. However, 
dose escalation to an entire target volume is not possible due to 
normal tissue toxicity. Many studies have shown that we’re on the 
limit of acceptable toxicity with our current treatment strategies. The 
term ‘dose painting’ implies non-uniformity within a target region, 
directing dose to sub regions of tumour to improve local control. 
Focusing a high-dose boost to a biological target volume, such as the 
hypermetabolic area on a PET scan or volumes defined on functional 
imaging like DW-MRI, could improve response rates.  IMRT has the 
ability to deliver non-uniform dose distributions. 
The use of this highly conformal external beam radiotherapy allows us 
to sculpt the dose around these sub volumes within tumor. Since 
studies have shown that both the primary tumor and the lymh nodes 
are important sites of failure, a radiotherapy technique which can 
target both is beneficial. Using simultaneous integrated boost 
techniques, this can be done without increasing overall treatment 
time and at the same time take into account both primary tumor and 
involved nodes.  Moreover, concomitant administration of 
chemotherapy is feasible and often indicated in these advanced 
tumors. And lastly, with the use of sequential (functional)  imaging we 
can adapt the treatment plan during the course of radiotherapy, 
based on the biological response of the tumor. 
The advantages are in favour of the use of external beam 
radiotherapy for dose escalation in oropharyngeal carcinomas. 
However, good selection tools are needed to define the patients 
whom might benefit from dose escalation. Both functional imaging 
and molecular features warrant further investigation. These studies 
are currently proceeding in order to define these subgroups. 
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Purpose/Objective: A resent study Appelt et al. (Int J Radiat 
OncolBiol Phys, 2012) demonstrated a significant dose-response 
relationship for tumour regression after preoperative chemo-
radiotherapy for locally advanced rectal cancers. 
BT boost in combination with EBRT is one feasible way of increasing 
the total tumour dose. To spare the non-involved parts of the rectal 
wall during BT, a shieldable applicator is desirable. Hansen et al. (Med 
Phys, 2006) demonstrated that physical shielding is preferable 
compared to sparing by increasing the distance using a multi channel 
applicator. While shieldable applicators are commonly used in 
brachytherapy, no shieldable MRI-compatible applicator is 
commercially available. 
The purpose of this study was to describe dosimetric properties of a 
prototype shieldable MRI-compatible applicator and investigate the 
feasibility of performing dose calculations using a commercially 
available Treatment Planning System (TPS). 
Materials and Methods: A semi-solid applicator made of 
polyoxymethylene (POM) is shown in Figure 1. The cavity allows 
placement of an MRI-visible 'dummy' shield during an MRI-procedure, 
while a high-Z shield (90° or 180°) can be applied during irradiation. 
 
  
Dose measurements were performed with an 192Ir HDR-source 
(microSelectron, Nucletron, An Elekta Company) using the PFD3G diode 
and BluePhantom (iba Dosimetry GmbH). 
Immersing the applicator into water radial dose distributions were 
acquired for each 45°. Measurements were performed for the central 
catheter and for the applicator (with or without the shields) 
respectively and were compared with the radial dose distribution from 
the TPS Oncentra® Brachy 4.1 (Nucletron, An Elekta Company). 
Results: The agreement of the measurements and the TPS for the 
central catheter was excellent at distances 0.5 mm to 40.0 mm from 
the applicator surface (relative error from –2.0 % to 1.4 %). At larger 
distances, the TPS increasingly underestimated the dose with an error 
of approx -5 % at a distance of 60 mm. 
At clinical relevant distances (5 mm to 15 mm from the applicator 
surface) an under-dosage (2.1 % to 4.7 %) was found for the solid part 
of the applicator compared to the TPS estimations. Near the 
applicator surface the under-dosage was 10 %. At increasing distances 
the difference decreased eventually resulting in a small relative over-
dosage far from the surface. General over-dosage behaviour was 
found for the hollow part. This was approx 8 % near the surface, and 
in the range of 3.9 % to 8.3 % at the clinical relevant distances. 
Transmission factors (50 mm from the applicator) for the shields were 
0.34 and 0.31, respectively and were easily incorporated into the TPS. 
Conclusions: The dosimetric properties of the prototype applicator 
were found to be acceptable. In clinical practice a renormalisation of 
